Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 3/20 | 0.70 |
| ▸ | ACHE | P22303 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthine SCHEMBL160198 | 0.92 | GDA (0.82) | GDAACHEALDH1A1PNPGRIA1 | |
| Uric Acid SCHEMBL5318287 | 0.92 | ALDH1A1 (0.64) | GDAACHEALDH1A1PNPGRIA1 | |
| Uric Acid SCHEMBL439505 | 0.92 | GDA (0.82) | GDAACHEALDH1A1PNP | |
| Xanthine SCHEMBL4295220 | 0.91 | GDA (0.79) | GDAACHEALDH1A1PNPGRIA1 | |
| Xanthine SCHEMBL4965 | 0.83 | GDA (1.00) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL2352524 | 0.83 | GDA (1.00) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL29669592 | 0.83 | GDA (1.00) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL2454001 | 0.82 | GDA (0.96) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL7044230 | 0.82 | GDA (0.96) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL7044227 | 0.82 | GDA (0.96) | GDAACHEALDH1A1PNPXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082296-A1 | TREATMENT OF MUSCLE ATROPHY USING DEXTRAN SULFATE | TX MEDIC AB (SE) | 2024-03-14 | — | — | US | disclosed |
| CN-115515594-A | Treatment of hyperuricemia | 腓特烈斯贝医院 | 2022-12-23 | — | — | CN | disclosed |
| CN-115068459-A | Application of abietic acid in preparation of medicine for treating and/or preventing hyperuricemia | 吉林大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-107468661-A | A kind of pharmaceutical composition containing Febustat | 迪沙药业集团有限公司 | 2017-12-15 | — | — | CN | disclosed |
| CN-103298466-B | Methods of combined treatment of theophylline and febuxostat | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-103298466-A | Methods of combined treatment of theophylline and febuxostat | TAKEDA PHARMACEUTICALS NORTH AMERICA INC | 2013-09-11 | — | — | CN | disclosed |
| EP-2242988-A1 | DEACTIVATING AN EXPLOSIVE COMPOSITION USING ENZYMES | Orica Explosives Technology Pty Ltd (AU) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009094716-A1 | DEACTIVATING AN EXPLOSIVE COMPOSITION USING ENZYMES | ORICA EXPLOSIVES TECHNOLOGY PTY LTD (AU) | 2009-08-06 | — | — | WO | disclosed |